查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1867516

病毒載體和質體DNA－全球市場佔有率和排名、總收入和需求預測（2025-2031年）

Viral Vector and Plasmid DNA - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 104 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球病毒載體和質體DNA市場預計在2024年達到6.67億美元，預計到2031年將達到41.87億美元，2025年至2031年的複合年成長率為30.2%。

病毒載體和質體DNA的生產是指基因治療、細胞治療、mRNA疫苗和下一代生物製藥所必需的上游工程。這包括生產高純度、高表達量的質體DNA，以及製備高效價、功能穩定的病毒載體，例如腺病毒、慢病毒和腺結合病毒（AAV）。這些製程在嚴格的GMP條件下進行，通常採用微生物或哺乳動物表現系統，並涉及發酵、純化、品管和包封等關鍵步驟。隨著生物技術的快速發展，該領域正從實驗室規模的生產向工業規模的生產發展，成為全球CDMO（合約研發生產機構）和生物技術公司的戰略重點。本報告僅關注用於研究目的的病毒載體和質體DNA。

隨著細胞和基因療法的商業化進程加速，全球對病毒載體和質體DNA的需求持續成長。隨著越來越多的CAR-T療法、基於AAV的基因療法和mRNA疫苗計畫進入臨床和商業化階段，高品質的載體材料已成為關鍵的瓶頸資源。同時，政府支持基因療法和疫苗生產在地化的政策推動了對符合GMP標準的載體平台的投資。 CDMO市場的擴張、生技公司外包趨勢的日益成長以及為降低生產成本而進行的製程最佳化，都促進了該領域的快速發展。

儘管市場需求強勁，但技術和監管方面的挑戰仍然存在。標準化程度有限，確保不同平台生產的一致性仍然是一項挑戰。品管標準要求很高，必須嚴格控制病毒安全性、核酸殘留和包封效率。此外，高品質的GMP生產能力仍集中在少數幾家跨國公司，新興企業往往面臨基礎設施投資、技術專長和人才招募方面的挑戰。監管審查也不斷加強，導致研發週期延長，進入門檻提高。

臨床研發管線的拓展和商業化產品的上市是該領域發展的關鍵驅動力。腺相關病毒（AAV）和慢病毒載體在罕見疾病、癌症免疫療法和神經系統疾病等領域的應用顯著增加。同時，質體DNA也被廣泛用作mRNA、疫苗、核酸藥物和CRISPR治療方法的起始模板或前驅物。製藥公司與合約研發生產機構（CDMO）之間的策略聯盟正在不斷擴大，旨在開發能夠支援多種下游應用的模組化、可擴充性的生產平台。

本報告旨在按地區/國家、類型和應用對全球病毒載體和質體DNA市場進行全面分析，重點關注總收入、市場佔有率和主要企業的排名。

本報告以2024年為基準年，按銷售收入對病毒載體和質體DNA市場規模、估算和預測進行了闡述，並包含了2020年至2031年的歷史數據和預測數據。定量和定性分析將幫助讀者制定病毒載體和質體DNA的業務和成長策略，評估市場競爭，分析自身在當前市場中的地位，並做出明智的商業決策。

市場區隔

公司

  • Thermo Fisher Scientific
  • Lonza
  • Azenta Life Sciences
  • Revvity
  • VectorBuilder
  • Takara Bio
  • GenScript Biotech
  • Gene Chem
  • Geno Meditech
  • PackGene Biotech
  • VIROVEK
  • OriGen
  • Vector BioLabs

按類型分類的細分市場

  • AAV
  • 慢病毒
  • 逆轉錄病毒
  • 腺病毒
  • DNA質體
  • 其他

應用領域

  • 製藥和生物製藥公司
  • 學術和研究機構

按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Viral Vector and Plasmid DNA was estimated to be worth US$ 667 million in 2024 and is forecast to a readjusted size of US$ 4187 million by 2031 with a CAGR of 30.2% during the forecast period 2025-2031.

Viral Vector and Plasmid DNA Manufacturing refers to the upstream manufacturing processes essential for gene therapy, cell therapy, mRNA vaccines, and next-generation biologics. It includes the production of high-purity, high-expression plasmid DNA and the preparation of high-titer, functionally stable viral vectors such as adenovirus, lentivirus, and adeno-associated virus (AAV). These processes must be conducted under stringent GMP conditions, often using microbial or mammalian expression systems, and involve key steps such as fermentation, purification, quality control, and encapsulation. With the rapid advancement of biotechnology, this sector is evolving from lab-scale production to industrial-scale manufacturing, becoming a strategic focus for CDMOs and biotech firms worldwide.In this report, we only study the Viral Vector and Plasmid DNA used for research.

As the commercialization of cell and gene therapies accelerates, global demand for viral vectors and plasmid DNA continues to grow. An increasing number of CAR-T therapies, AAV-based gene therapies, and mRNA vaccine programs are advancing into clinical and commercial stages, positioning high-quality vector materials as critical bottleneck resources. Meanwhile, supportive government policies promoting the localization of gene therapy and vaccine production are driving investment in GMP-compliant vector platforms. The expanding CDMO market, stronger outsourcing trends among biotech companies, and process optimization efforts lowering production costs are jointly propelling this sector toward rapid development.

Despite strong demand, the sector faces technical and regulatory hurdles. Standardization remains limited, with cross-platform consistency in production still difficult to achieve. The bar for quality control is high, requiring strict management of viral safety, residual nucleic acids, and encapsulation efficiency. Moreover, premium GMP capacity is still dominated by a few multinational firms, while emerging players often face challenges in infrastructure investment, technical expertise, and talent acquisition. Regulatory scrutiny is also intensifying, lengthening development timelines and raising entry thresholds.

Clinical pipeline expansion and commercial product launches are the primary growth drivers for this field. In indications such as rare diseases, cancer immunotherapy, and neurological disorders, the use of AAV and lentiviral vectors is increasing significantly. At the same time, plasmid DNA is widely used as a starting template or precursor for mRNA, vaccines, nucleic acid drugs, and CRISPR-based therapies. Strategic partnerships between pharma and CDMO players are proliferating to develop modular, scalable manufacturing platforms that can support a diverse array of downstream applications.

This report aims to provide a comprehensive presentation of the global market for Viral Vector and Plasmid DNA, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Viral Vector and Plasmid DNA by region & country, by Type, and by Application.

The Viral Vector and Plasmid DNA market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vector and Plasmid DNA.

Market Segmentation

By Company

  • Thermo Fisher Scientific
  • Lonza
  • Azenta Life Sciences
  • Revvity
  • VectorBuilder
  • Takara Bio
  • GenScript Biotech
  • Gene Chem
  • Geno Meditech
  • PackGene Biotech
  • VIROVEK
  • OriGen
  • Vector BioLabs

Segment by Type

  • AAV
  • Lentiviruses
  • Retroviruses
  • Adenoviruses
  • DNA Plasmids
  • Other

Segment by Application

  • Pharmaceutical and Biopharmaceutical Companies
  • Academics and Research Institutes

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Viral Vector and Plasmid DNA company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Viral Vector and Plasmid DNA in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Viral Vector and Plasmid DNA in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Viral Vector and Plasmid DNA Product Introduction
  • 1.2 Global Viral Vector and Plasmid DNA Market Size Forecast (2020-2031)
  • 1.3 Viral Vector and Plasmid DNA Market Trends & Drivers
    • 1.3.1 Viral Vector and Plasmid DNA Industry Trends
    • 1.3.2 Viral Vector and Plasmid DNA Market Drivers & Opportunity
    • 1.3.3 Viral Vector and Plasmid DNA Market Challenges
    • 1.3.4 Viral Vector and Plasmid DNA Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Viral Vector and Plasmid DNA Players Revenue Ranking (2024)
  • 2.2 Global Viral Vector and Plasmid DNA Revenue by Company (2020-2025)
  • 2.3 Key Companies Viral Vector and Plasmid DNA Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Viral Vector and Plasmid DNA Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Viral Vector and Plasmid DNA
  • 2.6 Viral Vector and Plasmid DNA Market Competitive Analysis
    • 2.6.1 Viral Vector and Plasmid DNA Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Viral Vector and Plasmid DNA Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vector and Plasmid DNA as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 AAV
    • 3.1.2 Lentiviruses
    • 3.1.3 Retroviruses
    • 3.1.4 Adenoviruses
    • 3.1.5 DNA Plasmids
    • 3.1.6 Other
  • 3.2 Global Viral Vector and Plasmid DNA Sales Value by Type
    • 3.2.1 Global Viral Vector and Plasmid DNA Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Viral Vector and Plasmid DNA Sales Value, by Type (2020-2031)
    • 3.2.3 Global Viral Vector and Plasmid DNA Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Pharmaceutical and Biopharmaceutical Companies
    • 4.1.2 Academics and Research Institutes
  • 4.2 Global Viral Vector and Plasmid DNA Sales Value by Application
    • 4.2.1 Global Viral Vector and Plasmid DNA Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Viral Vector and Plasmid DNA Sales Value, by Application (2020-2031)
    • 4.2.3 Global Viral Vector and Plasmid DNA Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Viral Vector and Plasmid DNA Sales Value by Region
    • 5.1.1 Global Viral Vector and Plasmid DNA Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Viral Vector and Plasmid DNA Sales Value by Region (2020-2025)
    • 5.1.3 Global Viral Vector and Plasmid DNA Sales Value by Region (2026-2031)
    • 5.1.4 Global Viral Vector and Plasmid DNA Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Viral Vector and Plasmid DNA Sales Value, 2020-2031
    • 5.2.2 North America Viral Vector and Plasmid DNA Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Viral Vector and Plasmid DNA Sales Value, 2020-2031
    • 5.3.2 Europe Viral Vector and Plasmid DNA Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Viral Vector and Plasmid DNA Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Viral Vector and Plasmid DNA Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Viral Vector and Plasmid DNA Sales Value, 2020-2031
    • 5.5.2 South America Viral Vector and Plasmid DNA Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Viral Vector and Plasmid DNA Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Viral Vector and Plasmid DNA Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Viral Vector and Plasmid DNA Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Viral Vector and Plasmid DNA Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Viral Vector and Plasmid DNA Sales Value, 2020-2031
    • 6.3.2 United States Viral Vector and Plasmid DNA Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Viral Vector and Plasmid DNA Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Viral Vector and Plasmid DNA Sales Value, 2020-2031
    • 6.4.2 Europe Viral Vector and Plasmid DNA Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Viral Vector and Plasmid DNA Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Viral Vector and Plasmid DNA Sales Value, 2020-2031
    • 6.5.2 China Viral Vector and Plasmid DNA Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Viral Vector and Plasmid DNA Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Viral Vector and Plasmid DNA Sales Value, 2020-2031
    • 6.6.2 Japan Viral Vector and Plasmid DNA Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Viral Vector and Plasmid DNA Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Viral Vector and Plasmid DNA Sales Value, 2020-2031
    • 6.7.2 South Korea Viral Vector and Plasmid DNA Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Viral Vector and Plasmid DNA Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Viral Vector and Plasmid DNA Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Viral Vector and Plasmid DNA Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Viral Vector and Plasmid DNA Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Viral Vector and Plasmid DNA Sales Value, 2020-2031
    • 6.9.2 India Viral Vector and Plasmid DNA Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Viral Vector and Plasmid DNA Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Thermo Fisher Scientific
    • 7.1.1 Thermo Fisher Scientific Profile
    • 7.1.2 Thermo Fisher Scientific Main Business
    • 7.1.3 Thermo Fisher Scientific Viral Vector and Plasmid DNA Products, Services and Solutions
    • 7.1.4 Thermo Fisher Scientific Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Thermo Fisher Scientific Recent Developments
  • 7.2 Lonza
    • 7.2.1 Lonza Profile
    • 7.2.2 Lonza Main Business
    • 7.2.3 Lonza Viral Vector and Plasmid DNA Products, Services and Solutions
    • 7.2.4 Lonza Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Lonza Recent Developments
  • 7.3 Azenta Life Sciences
    • 7.3.1 Azenta Life Sciences Profile
    • 7.3.2 Azenta Life Sciences Main Business
    • 7.3.3 Azenta Life Sciences Viral Vector and Plasmid DNA Products, Services and Solutions
    • 7.3.4 Azenta Life Sciences Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Azenta Life Sciences Recent Developments
  • 7.4 Revvity
    • 7.4.1 Revvity Profile
    • 7.4.2 Revvity Main Business
    • 7.4.3 Revvity Viral Vector and Plasmid DNA Products, Services and Solutions
    • 7.4.4 Revvity Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Revvity Recent Developments
  • 7.5 VectorBuilder
    • 7.5.1 VectorBuilder Profile
    • 7.5.2 VectorBuilder Main Business
    • 7.5.3 VectorBuilder Viral Vector and Plasmid DNA Products, Services and Solutions
    • 7.5.4 VectorBuilder Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
    • 7.5.5 VectorBuilder Recent Developments
  • 7.6 Takara Bio
    • 7.6.1 Takara Bio Profile
    • 7.6.2 Takara Bio Main Business
    • 7.6.3 Takara Bio Viral Vector and Plasmid DNA Products, Services and Solutions
    • 7.6.4 Takara Bio Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Takara Bio Recent Developments
  • 7.7 GenScript Biotech
    • 7.7.1 GenScript Biotech Profile
    • 7.7.2 GenScript Biotech Main Business
    • 7.7.3 GenScript Biotech Viral Vector and Plasmid DNA Products, Services and Solutions
    • 7.7.4 GenScript Biotech Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
    • 7.7.5 GenScript Biotech Recent Developments
  • 7.8 Gene Chem
    • 7.8.1 Gene Chem Profile
    • 7.8.2 Gene Chem Main Business
    • 7.8.3 Gene Chem Viral Vector and Plasmid DNA Products, Services and Solutions
    • 7.8.4 Gene Chem Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Gene Chem Recent Developments
  • 7.9 Geno Meditech
    • 7.9.1 Geno Meditech Profile
    • 7.9.2 Geno Meditech Main Business
    • 7.9.3 Geno Meditech Viral Vector and Plasmid DNA Products, Services and Solutions
    • 7.9.4 Geno Meditech Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Geno Meditech Recent Developments
  • 7.10 PackGene Biotech
    • 7.10.1 PackGene Biotech Profile
    • 7.10.2 PackGene Biotech Main Business
    • 7.10.3 PackGene Biotech Viral Vector and Plasmid DNA Products, Services and Solutions
    • 7.10.4 PackGene Biotech Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
    • 7.10.5 PackGene Biotech Recent Developments
  • 7.11 VIROVEK
    • 7.11.1 VIROVEK Profile
    • 7.11.2 VIROVEK Main Business
    • 7.11.3 VIROVEK Viral Vector and Plasmid DNA Products, Services and Solutions
    • 7.11.4 VIROVEK Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
    • 7.11.5 VIROVEK Recent Developments
  • 7.12 OriGen
    • 7.12.1 OriGen Profile
    • 7.12.2 OriGen Main Business
    • 7.12.3 OriGen Viral Vector and Plasmid DNA Products, Services and Solutions
    • 7.12.4 OriGen Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
    • 7.12.5 OriGen Recent Developments
  • 7.13 Vector BioLabs
    • 7.13.1 Vector BioLabs Profile
    • 7.13.2 Vector BioLabs Main Business
    • 7.13.3 Vector BioLabs Viral Vector and Plasmid DNA Products, Services and Solutions
    • 7.13.4 Vector BioLabs Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
    • 7.13.5 Vector BioLabs Recent Developments

8 Industry Chain Analysis

  • 8.1 Viral Vector and Plasmid DNA Industrial Chain
  • 8.2 Viral Vector and Plasmid DNA Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Viral Vector and Plasmid DNA Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Viral Vector and Plasmid DNA Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Viral Vector and Plasmid DNA Market Trends
  • Table 2. Viral Vector and Plasmid DNA Market Drivers & Opportunity
  • Table 3. Viral Vector and Plasmid DNA Market Challenges
  • Table 4. Viral Vector and Plasmid DNA Market Restraints
  • Table 5. Global Viral Vector and Plasmid DNA Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Viral Vector and Plasmid DNA Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Viral Vector and Plasmid DNA Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Viral Vector and Plasmid DNA Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Viral Vector and Plasmid DNA
  • Table 10. Global Viral Vector and Plasmid DNA Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vector and Plasmid DNA as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Viral Vector and Plasmid DNA Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Viral Vector and Plasmid DNA Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Viral Vector and Plasmid DNA Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Viral Vector and Plasmid DNA Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Viral Vector and Plasmid DNA Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Viral Vector and Plasmid DNA Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Viral Vector and Plasmid DNA Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Viral Vector and Plasmid DNA Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Viral Vector and Plasmid DNA Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Viral Vector and Plasmid DNA Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Viral Vector and Plasmid DNA Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Viral Vector and Plasmid DNA Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Viral Vector and Plasmid DNA Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Viral Vector and Plasmid DNA Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Viral Vector and Plasmid DNA Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Viral Vector and Plasmid DNA Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Viral Vector and Plasmid DNA Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Viral Vector and Plasmid DNA Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Thermo Fisher Scientific Basic Information List
  • Table 32. Thermo Fisher Scientific Description and Business Overview
  • Table 33. Thermo Fisher Scientific Viral Vector and Plasmid DNA Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Viral Vector and Plasmid DNA Business of Thermo Fisher Scientific (2020-2025)
  • Table 35. Thermo Fisher Scientific Recent Developments
  • Table 36. Lonza Basic Information List
  • Table 37. Lonza Description and Business Overview
  • Table 38. Lonza Viral Vector and Plasmid DNA Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Viral Vector and Plasmid DNA Business of Lonza (2020-2025)
  • Table 40. Lonza Recent Developments
  • Table 41. Azenta Life Sciences Basic Information List
  • Table 42. Azenta Life Sciences Description and Business Overview
  • Table 43. Azenta Life Sciences Viral Vector and Plasmid DNA Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Viral Vector and Plasmid DNA Business of Azenta Life Sciences (2020-2025)
  • Table 45. Azenta Life Sciences Recent Developments
  • Table 46. Revvity Basic Information List
  • Table 47. Revvity Description and Business Overview
  • Table 48. Revvity Viral Vector and Plasmid DNA Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Viral Vector and Plasmid DNA Business of Revvity (2020-2025)
  • Table 50. Revvity Recent Developments
  • Table 51. VectorBuilder Basic Information List
  • Table 52. VectorBuilder Description and Business Overview
  • Table 53. VectorBuilder Viral Vector and Plasmid DNA Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Viral Vector and Plasmid DNA Business of VectorBuilder (2020-2025)
  • Table 55. VectorBuilder Recent Developments
  • Table 56. Takara Bio Basic Information List
  • Table 57. Takara Bio Description and Business Overview
  • Table 58. Takara Bio Viral Vector and Plasmid DNA Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Viral Vector and Plasmid DNA Business of Takara Bio (2020-2025)
  • Table 60. Takara Bio Recent Developments
  • Table 61. GenScript Biotech Basic Information List
  • Table 62. GenScript Biotech Description and Business Overview
  • Table 63. GenScript Biotech Viral Vector and Plasmid DNA Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Viral Vector and Plasmid DNA Business of GenScript Biotech (2020-2025)
  • Table 65. GenScript Biotech Recent Developments
  • Table 66. Gene Chem Basic Information List
  • Table 67. Gene Chem Description and Business Overview
  • Table 68. Gene Chem Viral Vector and Plasmid DNA Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Viral Vector and Plasmid DNA Business of Gene Chem (2020-2025)
  • Table 70. Gene Chem Recent Developments
  • Table 71. Geno Meditech Basic Information List
  • Table 72. Geno Meditech Description and Business Overview
  • Table 73. Geno Meditech Viral Vector and Plasmid DNA Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Viral Vector and Plasmid DNA Business of Geno Meditech (2020-2025)
  • Table 75. Geno Meditech Recent Developments
  • Table 76. PackGene Biotech Basic Information List
  • Table 77. PackGene Biotech Description and Business Overview
  • Table 78. PackGene Biotech Viral Vector and Plasmid DNA Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Viral Vector and Plasmid DNA Business of PackGene Biotech (2020-2025)
  • Table 80. PackGene Biotech Recent Developments
  • Table 81. VIROVEK Basic Information List
  • Table 82. VIROVEK Description and Business Overview
  • Table 83. VIROVEK Viral Vector and Plasmid DNA Products, Services and Solutions
  • Table 84. Revenue (US$ Million) in Viral Vector and Plasmid DNA Business of VIROVEK (2020-2025)
  • Table 85. VIROVEK Recent Developments
  • Table 86. OriGen Basic Information List
  • Table 87. OriGen Description and Business Overview
  • Table 88. OriGen Viral Vector and Plasmid DNA Products, Services and Solutions
  • Table 89. Revenue (US$ Million) in Viral Vector and Plasmid DNA Business of OriGen (2020-2025)
  • Table 90. OriGen Recent Developments
  • Table 91. Vector BioLabs Basic Information List
  • Table 92. Vector BioLabs Description and Business Overview
  • Table 93. Vector BioLabs Viral Vector and Plasmid DNA Products, Services and Solutions
  • Table 94. Revenue (US$ Million) in Viral Vector and Plasmid DNA Business of Vector BioLabs (2020-2025)
  • Table 95. Vector BioLabs Recent Developments
  • Table 96. Key Raw Materials Lists
  • Table 97. Raw Materials Key Suppliers Lists
  • Table 98. Viral Vector and Plasmid DNA Downstream Customers
  • Table 99. Viral Vector and Plasmid DNA Distributors List
  • Table 100. Research Programs/Design for This Report
  • Table 101. Key Data Information from Secondary Sources
  • Table 102. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Viral Vector and Plasmid DNA Product Picture
  • Figure 2. Global Viral Vector and Plasmid DNA Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Viral Vector and Plasmid DNA Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Viral Vector and Plasmid DNA Report Years Considered
  • Figure 5. Global Viral Vector and Plasmid DNA Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Viral Vector and Plasmid DNA Revenue in 2024
  • Figure 7. Viral Vector and Plasmid DNA Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. AAV Picture
  • Figure 9. Lentiviruses Picture
  • Figure 10. Retroviruses Picture
  • Figure 11. Adenoviruses Picture
  • Figure 12. DNA Plasmids Picture
  • Figure 13. Other Picture
  • Figure 14. Global Viral Vector and Plasmid DNA Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 15. Global Viral Vector and Plasmid DNA Sales Value Market Share by Type, 2024 & 2031
  • Figure 16. Product Picture of Pharmaceutical and Biopharmaceutical Companies
  • Figure 17. Product Picture of Academics and Research Institutes
  • Figure 18. Global Viral Vector and Plasmid DNA Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 19. Global Viral Vector and Plasmid DNA Sales Value Market Share by Application, 2024 & 2031
  • Figure 20. North America Viral Vector and Plasmid DNA Sales Value (2020-2031) & (US$ Million)
  • Figure 21. North America Viral Vector and Plasmid DNA Sales Value by Country (%), 2024 VS 2031
  • Figure 22. Europe Viral Vector and Plasmid DNA Sales Value, (2020-2031) & (US$ Million)
  • Figure 23. Europe Viral Vector and Plasmid DNA Sales Value by Country (%), 2024 VS 2031
  • Figure 24. Asia Pacific Viral Vector and Plasmid DNA Sales Value, (2020-2031) & (US$ Million)
  • Figure 25. Asia Pacific Viral Vector and Plasmid DNA Sales Value by Region (%), 2024 VS 2031
  • Figure 26. South America Viral Vector and Plasmid DNA Sales Value, (2020-2031) & (US$ Million)
  • Figure 27. South America Viral Vector and Plasmid DNA Sales Value by Country (%), 2024 VS 2031
  • Figure 28. Middle East & Africa Viral Vector and Plasmid DNA Sales Value, (2020-2031) & (US$ Million)
  • Figure 29. Middle East & Africa Viral Vector and Plasmid DNA Sales Value by Country (%), 2024 VS 2031
  • Figure 30. Key Countries/Regions Viral Vector and Plasmid DNA Sales Value (%), (2020-2031)
  • Figure 31. United States Viral Vector and Plasmid DNA Sales Value, (2020-2031) & (US$ Million)
  • Figure 32. United States Viral Vector and Plasmid DNA Sales Value by Type (%), 2024 VS 2031
  • Figure 33. United States Viral Vector and Plasmid DNA Sales Value by Application (%), 2024 VS 2031
  • Figure 34. Europe Viral Vector and Plasmid DNA Sales Value, (2020-2031) & (US$ Million)
  • Figure 35. Europe Viral Vector and Plasmid DNA Sales Value by Type (%), 2024 VS 2031
  • Figure 36. Europe Viral Vector and Plasmid DNA Sales Value by Application (%), 2024 VS 2031
  • Figure 37. China Viral Vector and Plasmid DNA Sales Value, (2020-2031) & (US$ Million)
  • Figure 38. China Viral Vector and Plasmid DNA Sales Value by Type (%), 2024 VS 2031
  • Figure 39. China Viral Vector and Plasmid DNA Sales Value by Application (%), 2024 VS 2031
  • Figure 40. Japan Viral Vector and Plasmid DNA Sales Value, (2020-2031) & (US$ Million)
  • Figure 41. Japan Viral Vector and Plasmid DNA Sales Value by Type (%), 2024 VS 2031
  • Figure 42. Japan Viral Vector and Plasmid DNA Sales Value by Application (%), 2024 VS 2031
  • Figure 43. South Korea Viral Vector and Plasmid DNA Sales Value, (2020-2031) & (US$ Million)
  • Figure 44. South Korea Viral Vector and Plasmid DNA Sales Value by Type (%), 2024 VS 2031
  • Figure 45. South Korea Viral Vector and Plasmid DNA Sales Value by Application (%), 2024 VS 2031
  • Figure 46. Southeast Asia Viral Vector and Plasmid DNA Sales Value, (2020-2031) & (US$ Million)
  • Figure 47. Southeast Asia Viral Vector and Plasmid DNA Sales Value by Type (%), 2024 VS 2031
  • Figure 48. Southeast Asia Viral Vector and Plasmid DNA Sales Value by Application (%), 2024 VS 2031
  • Figure 49. India Viral Vector and Plasmid DNA Sales Value, (2020-2031) & (US$ Million)
  • Figure 50. India Viral Vector and Plasmid DNA Sales Value by Type (%), 2024 VS 2031
  • Figure 51. India Viral Vector and Plasmid DNA Sales Value by Application (%), 2024 VS 2031
  • Figure 52. Viral Vector and Plasmid DNA Industrial Chain
  • Figure 53. Viral Vector and Plasmid DNA Manufacturing Cost Structure
  • Figure 54. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 55. Bottom-up and Top-down Approaches for This Report
  • Figure 56. Data Triangulation
  • Figure 57. Key Executives Interviewed